Company intelligence / Profile preview

CHINAGENE TECH

Ownership: Private
Development stage: Other

Overview

Exploratory clinical trial of ZVS101e for Bietti crystalline dystrophy showed good safety and efficacy. The product received IND approvals from both NMPA and FDA in December 2022 for treatment of crystallization-like retinitis pigmentosa caused by CYP4V2 biallelic mutations.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

1 asset

ZVS101e

IND

Indications: Bietti crystalline dystrophy, Crystallization-like retinitis pigmentosa

Partnerships

OBiO Technology (Shanghai) Corp., Ltd. (strategic agreement for commercial manufacturing services)

Beyond the preview

Go deeper on CHINAGENE TECH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHINAGENE TECH.

Explore the full profile